Preferential Ebola virus glycoprotein recognition 16–17 years after Bundibugyo virus infection
Preprint
- 26 August 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
The re-emergence of Bundibugyo virus (BDBV), for which no licensed vaccine is available, has created an urgent need for human immunological evidence to inform evaluation of existing filovirus countermeasures. We measured IgG binding to BDBV, Ebola virus (EBOV)-Mayinga and Sudan virus (SUDV)-Gulu and SUDV-Boniface glycoproteins in 40 PCR-confirmed BDBV survivors sampled 16–17 years after infection. BDBV-specific IgG was detected in 22/40 participants (55.0%), while heterologous recognition was most frequent for EBOV-Mayinga (23/40, 57.5%), compared with SUDV-Gulu (5/40, 12.5%) and SUDV-Boniface (3/40, 7.5%). BDBV and EBOV-Mayinga responses were strongly correlated (Spearman ρ = 0.90), with recognition of both glycoproteins in 20/40 participants (50.0%). In 21 participants with detectable binding, EBOV-Mayinga endpoint titres were significantly higher than BDBV titres and remained positively correlated. These findings support functional evaluation of EBOV-based and broadly reactive filovirus countermeasures for potential relevance to BDBV.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Cross-border transmission of Ebola virus disease caused by Bundibugyo virus into Uganda, 2026The Lancet Infectious Diseases, 2026
- Resilience and residuals beyond containment — The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational studyNew Microbes and New Infections, 2025
- Molecular analysis of the 2012 Bundibugyo virus disease outbreakCell Reports Medicine, 2021
- Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort studyThe Lancet Infectious Diseases, 2021
- Longitudinal Analysis of the Human B Cell Response to Ebola Virus InfectionCell, 2019
- Achieving cross-reactivity with pan-ebolavirus antibodiesCurrent Opinion in Virology, 2019
- Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against EbolavirusesCell, 2017
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)The Lancet, 2017
- Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus InfectionCell, 2016
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal ruleNature Reviews Microbiology, 2009